ID   A-204/PazR
AC   CVCL_QY41
SY   PazR/A204
DR   PRIDE; PXD005536
DR   Wikidata; Q54605983
RX   PubMed=28842319;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI_71219; Pazopanib (Votrient).
CC   Sequence variation: Mutation; HGNC; HGNC:11103; SMARCB1; Simple; p.Gln182Alafs*28 (c.543_544delTC); Zygosity=Heterozygous (from parent cell line).
CC   Omics: Proteomics; PTM; Phosphorylation.
CC   Derived from site: In situ; Muscle; UBERON=UBERON_0001630.
DI   NCIt; C8971; Embryonal rhabdomyosarcoma
DI   ORDO; Orphanet_99757; Embryonal rhabdomyosarcoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1058 ! A-204
SX   Female
AG   1Y
CA   Cancer cell line
DT   Created: 05-03-18; Last updated: 10-04-25; Version: 9
//
RX   PubMed=28842319; DOI=10.1016/j.jprot.2017.08.015; PMCID=PMC5673060;
RA   Vyse S., McCarthy F., Broncel M., Paul A., Wong J.P., Bhamra A.,
RA   Huang P.H.;
RT   "Quantitative phosphoproteomic analysis of acquired cancer drug
RT   resistance to pazopanib and dasatinib.";
RL   J. Proteomics 170:130-140(2018).
//